Bristol的长效氨甲苯唑头孢菌素在新的头孢菌素中,Bristol的氨甲苯唑头孢菌素(Ceforanide)、Fujisawa的去甲噻肟头孢菌素(Ceftizoxime)和Abbott、Tak-eda的氨噻肟唑头孢菌素(SCE-1365)似乎是已进入了美国临床试验的最后阶段,因此可以预期它们将随着氧哌羟苯唑头孢菌素、氨噻肟头孢菌素和羟羧氧酰胺菌素投放于美国市场。Bristol的氨甲苯唑头孢菌素的抗菌谱可与象羟苄四唑头孢菌素那样的第二代头孢菌素相匹敌。由于它在人体内具有相对地长 Bristol’s long acting methotrexate cephalosporins Among the new cephalosporins, ceforanide of Bristol, ceftizoxime of Fujisawa and ammonia of Abbott, Tak-eda Thiaoxime cephalosporin (SCE-1365) appears to have entered the final stages of the U.S. clinical trial and therefore it is expected that they will follow cefoperazone, cefotaxime, and oxycarboxamide Mycin placed in the United States market. The antibacterial spectrum of cefmenoxime cephalosporin of Bristol is comparable to that of second-generation cephalosporins like cephalosporin. Because it has relatively long in the human body